Therapeutic Asset Ratings

480 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Sacituzumab Tirumotecan Solid Tumor	Merck Sharp & Dohme LLC	P2	CCC (50)
Si-B003 Solid Tumor	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CCC (50)
Tazemetostat Solid Tumor	Prisma Health-Upstate	P2	CCC (50)
Technetium [99Mtc]-H7Nd Solid Tumor	Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.	P2	CCC (50)
Tepotinib Solid Tumor	Helsinki University Central Hospital	P2	CCC (50)
wx390 Solid Tumor	Shanghai Jiatan Pharmatech Co., Ltd	P2	CCC (50)
Zimberelimab Solid Tumor	Compugen Ltd	P2	CCC (50)
Adagrasib Solid Tumor	Mirati Therapeutics Inc.	P2	CCC (49)
BMS 986253 Solid Tumor	Yana Najjar	P2	CCC (49)
DOTATOC Solid Tumor	MedSIR	P2	CCC (48)
Romidepsin Solid Tumor	University of Rochester	P1	CCC (48)
[18f]f-resca-rt4 Solid Tumor	RenJi Hospital	P2/3	CCC (48)
[18F]F-RESCA-T4 Solid Tumor	RenJi Hospital	P2/3	CCC (48)
[68ga]ga-nota-rt4 Solid Tumor	RenJi Hospital	P2/3	CCC (48)
[68ga]ga-nota-t4 Solid Tumor	RenJi Hospital	P2/3	CCC (48)
Acasunlimab Solid Tumor	Genmab	P1/2	CCC (48)
al8326 Solid Tumor	Advenchen Laboratories Nanjing Ltd.	P1/2	CCC (48)
bi 853520 Solid Tumor	InxMed (Shanghai) Co., Ltd.	P1/2	CCC (48)
Eflornithine Solid Tumor	Aminex Therapeutics, Inc.	P1/2	CCC (48)
ERIBULIN/FARLETUZUMAB ANTIBODY DRUG CONJUGATE Solid Tumor	Eisai Inc.	P1/2	CCC (48)
Hmpl-453 Solid Tumor	Hutchison Medipharma Limited	P1/2	CCC (48)
iah0968 Solid Tumor	SUNHO（China）BioPharmaceutical CO., Ltd.	P2/3	CCC (48)
Iodixanol Solid Tumor	Brian Henick, MD	P1/2	CCC (48)
TESTOSTERONE UNDECYLATE Solid Tumor	Aminex Therapeutics, Inc.	P1/2	CCC (48)
Tiragolumab Solid Tumor	Hoffmann-La Roche	P2	CC (47)

Showing 76 to 100 of 480 assets

PreviousPage 4 of 20Next